Datroway (datopotamab deruxtecan-dlnk)

What is Datroway (datopotamab deruxtecan-dlnk) for?

Datroway (datopotamab deruxtecan-dlnk) is a prescription medicine for the treatment of unresectable or metastatic HR-positive, HER2-negative breast cancer [1].

Datroway (datopotamab deruxtecan-dlnk) is available as lyophilized powder for injection (100 mg in single-dose vials) [1].

How does Datroway (datopotamab deruxtecan-dlnk) work?

Datroway (datopotamab deruxtecan-dlnk) is a type of targeted cancer treatment known as an antibody-drug conjugate. It works by combining a special antibody that seeks out a protein called Trop-2—often found on cancer cells—with a powerful cancer-killing medicine. Once it attaches to a Trop-2-positive cancer cell, the whole package is taken inside the cell, where the medicine is released. This medicine then damages the cell’s DNA, leading to cell death [1].

Where has Datroway (datopotamab deruxtecan-dlnk) been approved?

Datroway (datopotamab deruxtecan-dlnk) is approved by the PMDA in Japan, and the FDA in the USA [1]. It has also received a positive recommendation from the CHMP in the EU, meaning that EMA approval is expected soon [3].

References:

HIGHLIGHTS OF PRESCRIBING INFORMATION. Accessdata.fda.gov, Accessed 25 March 2025.

Datroway (datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer. AstraZeneca, Accessed 25 March 2025. 

Datroway,EMA.europe.eu, Accessed 25 March 2025.